Effects of NT-0796 in Healthy Volunteers and Patients with Parkinson’s Disease

2023-503203-29-00 Protocol NT-0796-P002 Human pharmacology (Phase I) - Other Ended

Start 12 Apr 2023 · End 18 Dec 2023 · Status Ended · 1 EU/EEA countries · 1 sites · Protocol NT-0796-P002

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ended
Participants planned 14
Countries 1
Sites 1

Parkinson's Disease

Key facts

Sponsor
Nodthera Limited
Participant type
Healthy volunteers, Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Nervous System Diseases [C10]
Trial duration
12 Apr 2023 → 18 Dec 2023
Decision date (initial)
2023-04-12
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Parkinson's Disease

VersionLevelCodeTermSystem organ class
21.1 LLT 10013113 Disease Parkinson's 10029205

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Nodthera Limited

Sponsor organisation
Nodthera Limited
Address
Mansion House, Chesterford Park, Little Chesterford Chesterford Park Little Chesterford
City
Saffron Walden
Postcode
CB10 1XL
Country
United Kingdom

Scientific contact point

Organisation
Nodthera Limited
Contact name
Sarah Director

Public contact point

Organisation
Nodthera Limited
Contact name
Sarah Director

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Netherlands Ended 14 1
Rest of world 0

Investigational sites

Netherlands

1 site · Ended
QPS Netherlands B.V.
Clinical Pharmacology, Hanzeplein 1, 9713 GZ, Groningen

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Netherlands 2023-04-12 2023-12-18 2023-04-13

Application history

4 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2023-03-13 Netherlands Acceptable
2023-04-12
2023-04-12
2 NON SUBSTANTIAL MODIFICATION NSM-1 2023-07-05 Netherlands Acceptable
2023-04-12
2023-07-05
3 SUBSTANTIAL MODIFICATION SM-1 2023-07-05 Netherlands Acceptable
2023-07-19
2023-07-19
4 NON SUBSTANTIAL MODIFICATION NSM-2 2023-09-11 Netherlands Acceptable
2023-07-19
2023-09-11